Dr. Goel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Yawkey 12, Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-335-3937
Education & Training
The University of Adelaide Faculty of Health SciencesClass of 1996
Certifications & Licensure
MA State Medical License 2018 - 2026
Clinical Trials
- Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Start of enrollment: 2017 May 26
Publications & Presentations
PubMed
- Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer o...Ana C Garrido-Castro, Noah Graham, Lestat R Ali, Christina Herold, Jennifer Desrosiers
Journal for Immunotherapy of Cancer. 2025-02-25 - A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer.Shom Goel, Bojana Jovanović, Xiangying Chu, Melissa Hughes, Timothy K Erick
Clinical Cancer Research. 2025-02-05 - Intracellular zinc protects tumours from T cell-mediated cytotoxicity.Emily J Lelliott, Jonathan Naddaf, Katherine Ganio, Jessica Michie, Shelly Wang
Cell Death and Differentiation. 2024-12-01
Press Mentions
Breast Cancer Updates from ESMO 2022September 21st, 2022
Studies Highlight ‘Potential New Targets for Immunotherapy’August 22nd, 2017
Drug Combination Drives HER2-Positive Breast Cancer Brain Metastases into Long-Term Remission in Mouse StudyJune 6th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
